LAUSR

T he administration of monoclonal antibodies against SARS-CoV-2 reduce the risk of COVID-19–related hospitalization and death. 1 Solid organ transplant (SOT) patients with SARS-CoV-2 infection have higher rates of severe disease progression compared with the general pop-ulation. The availability of such treatments could represent a key therapeutic tool in the fight against COVID-19 and its sequelae. Nevertheless, real world data regarding the use of monoclonal antibodies in these patients are scarce 2 and are limited to few case series based on Casirivimab/ Imdevimab or Bamlanivimab/Etesevimab administration. 3,4 No published study evaluated efficacy and safety of Sotrovimab in this setting so far. We present a small case series of SOT recipients diag-nosed with SARS-CoV-2 infection (positive SARS-CoV-2 RNA detection by RT-PCR on rhino-oropharyngeal swab) treated with sotrovimab (single 500 mg IV dose) at the Division of Infectious Diseases of Federico II University Hospital of Naples, Italy, between December 15, 2021, and January 15, 2022.